Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company develops medications capable of once-daily dosing using its proprietary drug delivery platform technology, Precision Timed Release. Its drug candidates include CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials, as well as CTx-1302 (dextroamphetamine), which is in Phase 1/2 clinical pharmacology and Phase 3 clinical efficacy and safety trials for the treatment of ADHD in children, adolescents, and adults; and CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and related disorders. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Metrics to compare | CING | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCINGPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.3x | −0.1x | −0.5x | |
PEG Ratio | −0.01 | 0.01 | 0.00 | |
Price/Book | 3.6x | 0.9x | 2.6x | |
Price / LTM Sales | - | 0.8x | 3.3x | |
Upside (Analyst Target) | 383.8% | 189.8% | 40.3% | |
Fair Value Upside | Unlock | 2.3% | 5.1% | Unlock |